This web site is designed for accessibility. Content is obtainable and functional to any browser or Internet device. This page's full visual experience is available in a graphical browser that supports web standards. See reasons to upgrade your browser.

Leonard Mausner

Scientist


Telephone:  (631) 344-4457
e-mail:  mausner@bnl.gov

Research Interests

  • Development of high specific activity radionuclides for nuclear oncology
  • Techniques for the production of yttrium-86 for tumor imaging with PET prior to administration of Yttrium-90 labeled antibody for therapy and copper-67, scandium-47, and mercury-195m for tumor therapy with somatostatin-type receptor binding peptide and with angiogenic peptides.

 Education & Concurrent Positions

  • B.S. Massachusetts Institute of Technology, 1968.
  • M.A. Princeton University, 1972.
  • Ph.D. Princeton University, 1975.
  • Assistant Scientist, Argonne National Laboratory, 1977-1981.
  • Associate Scientist, Medical Department, BNL, 1981-1983.
  • Head, Brookhaven Linac Isotope Producer (BLIP) and isotope production/distribution program, BNL, 1983-present.
  • Scientist, BNL. 1983-2003.
  • Senior Scientist, BNL. 2003-present.

Selected Publications

  • Mausner L.F. and Mirzadeh S.  Reactor Production of Radionuclides, in: Handbook of Radiopharmaceuticals: Radiochemistry and Applications, M.J. Welch and C.Redvanly eds. John Wiley & Sons Ltd., NY (2003).
  • Kolsky K.L., Meinken G.E.,Kurczak S., Mausner L.F. and Srivastava S.C.  Production of high specific activity Ge-68 at Brookhaven National Laboratory. J. Radioanalytical and Nuclear Chemistry, 2005; 263:553-557.
  • DeNardo S.J., DeNardo G.L., Kukis D.L., Shen S., Kroger L.A., DeNardo D.A., Goldstein D.S., Mirick G.R., Salsko Q., Mausner L.F., Srivastava S.C. and Meares C.F.  Cu-67-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity, tumor regressio in patients with lymphoma. J. Nuclear Medicine, 1999; 40(2):302-310.
  • PubMed
  • Kolsky K.L., Joshi V., Mausner L.F., Srivastava S.C.  Radiochemical purification of no-carrier-added scandium-47 for radioimmunotherapy. Int. J. Applied Radiation and Isotopes, 1998; 49(12):1541-1549.
  • PubMed
  • Mausner L.F., Kolsky K.L., Joshi V. and Srivastava S.C.  Radionuclide development at BNL for nuclear medicine therapy. Int. J. Applied Radiation and Isotopes, 1998; 49(4):285-294.
  • PubMed
  • Srivastava S.C., Atkins H.L., Krishnamurthy G.T., Zanzi I., Silberstein G., Mainken G., Mausner L.F., Swailem F., D’Alessandro T., Cabahug C.J., Lau Y., Park T. and Madajewicz S.  Treatment of metastatic bone pain with Tin-117m stanic diethylenetriaminepentaacetic acid: A phase I/II clinical study. Clinical Cancer Research, 1998;4(1):61-68.
  • PubMed

Top of Page

Last Modified: April 25, 2012
Please forward all questions about this site to: Nicholas J. Franco